CNTB (Connect Biopharma Holdings) ROCE % : -51.75% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Connect Biopharma Holdings's annualized ROCE % for the quarter that ended in Mar. 2025 was -51.75%.

Connect Biopharma Holdings ROCE % Historical Data

The historical data trend for Connect Biopharma Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings ROCE % Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-113.82

-93.23

-54.59

-53.02

-23.04

Connect Biopharma Holdings Quarterly Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Mar24	Jun24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial							-	-49.50	73.38	-	-51.75

Connect Biopharma Holdings ROCE % Calculation

Connect Biopharma Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-22.452	/	( ( (127.375 - 25.293)	+	(101.284 - 8.462) )	/ 2 )
	=	-22.452	/	( (102.082	+	92.822)	/ 2 )
	=	-22.452	/	97.452
	=	-23.04 %

Connect Biopharma Holdings's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-45.788	/	( ( (101.284 - 8.462)	+	(92.685 - 8.565) )	/ 2 )
	=	-45.788	/	( ( 92.822	+	84.12 )	/ 2 )
	=	-45.788	/	88.471
	=	-51.75 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Connect Biopharma Holdings (NAS:CNTB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Connect Biopharma Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.